Introduction
Pheochromocytoma (PCC) and paraganglioma (PGL) are rare chromaffin cell tumours that synthesise, but not always secrete catecholamines and their metabolites. Contrary to traditional belief that only 10 % of these tumours metastasise to nonchromaffin sites, such as lung, bone, liver or lymph nodes, higher prevalences of 26 and 35 % has been recently observed in malignant PCC and PGL respectively [1, 2] .
Despite the recent discovery of certain germline mutations, such as succinate dehydrogenase subunit B (SDHB) in an aggressive tumour [3, 4] , at present there is no single marker that can objectively distinguish between benign and malignant PCC/PGL [5] [6] [7] [8] . The diagnosis of malignancy is solely based on the presence of distant metastasis. Hence, imaging techniques play a pivotal role in tumour localisation and mapping.
In addition, surveillance imaging has often been incorporated as part of a monitoring tool in non-functional tumours.
Although anatomical imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) is often the first-line imaging modality [10] , functional imaging is commonly needed to clarify equivocal lesions detected by anatomical imaging. Furthermore, functional imaging has been primarily recommended to exclude the possibility of multifocal or occult metastatic disease during initial workup in high risk groups, especially in young patients <40 years old and patients with adrenal PCC of >5 cm in size [9, 10] .
Even though 123/131 I-metaiodobenzylguanidine ( 123/131 I-MIBG) scintigraphy is an excellent functional imaging tool in adrenal PCC, it has demonstrated low sensitivity in extraadrenal PGL and metastatic PCC/PGL [11] [12] [13] . In recent years, 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) has been suggested as a preferred functional imaging tool in malignant PCC/PGL, particularly in SDH and von Hippel-Lindau (VHL) germline mutation tumours or when de-differentiated tumour is suspected [15] [16] [17] .
The discovery of somatostatin receptors (SSTR) expression, especially subtypes 2A and 3, in PCC/PGL has promoted the use of 111 In-octreotide or 99m Tc-HYNIC-TOC scintigraphy to locate these tumours [18] [19] [20] [21] . Despite the advancement of single-photon emission computed tomography (SPECT)/CT imaging, PET/CT imaging using 68 Ga-DOTApeptides (  68 Ga-DOTA-TOC,  68 Ga-DOTA-NOC and  68 Ga-DOTA-TATE) as radiotracers continues to provide better image quality [22] .
Although the diagnostic yield of 68 Ga-DOTA-peptides PET/CT in the detection of PCC/ PGL has been evaluated in several studies [23] [24] [25] [26] , its promising role in these tumours is still not largely accepted.
68
Ga-DOTA-peptides are still considered as experimental tracers in recent guidelines [27] . Hence, the aim of this study was to evaluate the diagnostic performance of 68 Ga-DOTA-TATE PET/CT in comparison to 131 I-MIBG scintigraphy and 18 F-FDG PET/CT in the mapping of these diseases. 123 I-MIBG is not available in our centre.
Materials and Methods

Patients
Seventeen consecutive patients (males:females=8:9; aged 13-68 years, median age 40 years) with histopathologically proved PCC/PGL followed-up in Putrajaya Hospital from December 2011 to June 2013 were recruited in this prospective study. Inclusion criteria were as follows: (1) Ga-DOTATATE study was 4 months. The study protocol was approved by the local ethics committee, and written informed consent was obtained from all patients. Ga-DOTATATE PET/CT Imaging Protocol PET-CT imaging was performed on the dedicated GE Discovery ST scanner (GE Healthcare, Chalfont St Giles, Bucks., UK), combining a PET unit and an eight-slice CT unit. No specific patient preparation was instructed prior to this examination. Patients were administered 148-185 MBq (4-5 mCi) of 68 Ga-DOTATATE intravenously. Image acquisition was performed 45-60 min post-injection with a whole-body field of view (vertex to mid thigh).
Transmission CT images for attenuation correction were performed with the exposure factors for all examinations of 120 kVp and 80 mA in 0.8 s. Emission PET images were obtained in two-dimensional mode, at a rate of 4 min per bed position with a three-slice overlap between consecutive bed positions. Transaxial PET data were reconstructed using filtered backprojection. The CT data for PET were reconstructed to axial slices of 3.3-mm thick.
F-FDG PET/CT Imaging Protocol
Patients were fasted for at least 4 h prior to examination. Upon admission, the patient's body weight was taken and blood glucose level was recorded. An activity of 6 MBq/kg (range, 285-460 MBq) of 18 F-FDG was administered intravenously. PET-CT imaging was performed on the dedicated GE Discovery ST scanner (GE Healthcare), combining a PET unit and an eight-slice CT unit. Image acquisition was performed 45-60 min post-injection with a whole-body field of view (vertex to mid-thigh).
Transmission CT images for attenuation correction were performed with the exposure factors for all examinations of 120 kVp and 80 mA in 0.8 s. No intravenous CT contrast was administered. Emission PET images were obtained in twodimensional mode, at a rate of 4 min per bed position with a three-slice overlap between consecutive bed positions. Transaxial PET data were reconstructed using filtered backprojection. The CT data for PET were reconstructed to axial slices of 3.3 mm thick.
Image Interpretation
All 68 Ga-DOTATATE and 18 F-FDG PET/CT images were reviewed on a GE Advantage 4.2 workstation (GE Healthcare), whereas 131 I-MIBG scintigraphy images were reviewed on an ESOFT Syngo workstation (Siemens Healthcare) by two experienced nuclear medicine physicians. CT and MRI images were re-evaluated on a Mac-based OsiriX workstation by an experienced radiologist. The site and number of lesions were evaluated.
Positive uptakes on PET findings were based on visual assessment and maximum standardised uptake values (SUV max ) with correction for body weight.
131
I-MIBG uptake in the adrenals was considered to be normal if it was mild, symmetrical and not enlarged. Positive findings on CT and MRI were based on specific appearance of malignant disease.
Statistical Analysis
Out of the 17 patients, 12 patients underwent all three modalities, whereas 5 patients underwent 68 Ga-DOTATATE and 131 I-MIBG without 18 F-FDG. Therefore, analysis on 131 I-MIBG scintigraphy and 68 Ga-DOTATATE PET/CT was based on a total of 17 patients, whereas analysis on 18 F-FDG PET-CT was evaluated in 12 patients by excluding patients with no 18 F-FDG PET-CT study. Histopathological confirmation is used as the Bgold standard^for most of the diagnostic studies. In the presence of extensive metastases, where biopsy or surgical excision of all lesions or previous surgical sites was not feasible, a composite reference standard was adopted to validate the findings by incorporating both anatomical and functional imaging information.
Analysis was assessed on a per-patient and on per-lesion basis. In the per-lesion analysis, lesion was considered true positive when (1) there were positive histopathological results or (2) there was an unequivocal focus of abnormally increased tracer uptake detected by either 18 F-FDG PET/CT, 68 Ga-DOTATATE PET/CT or 131 I-MIBG imaging in a nonphysiological site, which was confidently judged as disease by the reporting physicians. A true-negative lesion was considered when no uptake was seen by either I-MIBG imaging in a lesion detected by contrasted/non-contrasted CT or MRI. Lesions that were judged insufficient to establish the diagnosis (equivocal focus) were excluded from the analysis. In the per-patient analysis, metastatic disease was considered positive when at least one positive lesion per patient was detected.
With regard to histopathological correlation, all patients had undergone primary tumour resection with histopathological confirmation. In 13 out of 17 patients, apart from primary removal, 5 patients had undergone three or more metasectomies, whereas 6 patients had two matasectomies and 2 patients had one metasectomy. Out of the four patients without histopathogical confirmation of metastasis, two patients were found to have all negative scans, whereas two patients showed extensive metastases, where biopsy or metasectomy in these two patients was technically impossible and not justified.
SPSS Software (version 19.0) was used to perform statistical analysis. Sensitivity and accuracy were calculated, and significance between the values determined using McNemar's test. A p value of less than 0.05 was considered statistical significant.
Results
Baseline Characteristics
The distribution of patients' characteristics is summarised in Table 1 . Based on World Health Organisation (WHO) criteria [3] , ten patients were diagnosed as PCC and seven patients as PGL. Prior to the study, 76 % (13/17) of patients had the metastatic status confirmed by CT, MRI or metasectomy. In the remaining patients, suspicion of metastasis was based on either equivocal lesion(s) on contrasted CT or MRI, primary adrenal mass of >5 cm in size or uncontrolled high blood pressure on more than two anti-hypertensive medications.
Out of 15 patients that underwent 24-h catecholamine urine test to confirm the functional status of PCC/PGL tumour, 9 patients demonstrated raised urinary catecholamine level. Based on pedigree analysis, three (18 %) patients were diagnosed as familial syndrome; whereas 82 % of patients were considered as sporadic cases. Genetic confirmation was unavailable during the study.
Per-Patient Analysis
Fifteen out of 17 patients were positive of having metastatic disease.
68 Ga-DOTATATE PET/CT correctly identified 14 positive patients, whereas only 7 patients were detected by 
Per-Lesion Analysis
In total (patient, n=17), 472 true-positive lesions were detected; of which, 432 lesions were identified by (Fig. 1) .
On lesion-based analysis, the sensitivity and accuracy of (Table 2) .
In 12 patients who underwent all three modalities, 6 patients were shown to have osseous metastases; of which a total of 230, 98 and 9 metastatic lesions were detected by 68 Ga-DOTATATE PET/CT, 18 F-FDG PET/CT and 131 I-MIBG respectively. One patient demonstrated a rare PCC metastasis to the right breast on all three modalities (Fig. 1) .
The range of measured SUV max over 68 Ga-DOTATATE uptake lesions was from 1.6 to 89.8; whereas the range of SUV max over 18 F-FDG uptake lesions was from 2.5 to 62.3. Our data show no difference between functional and nonfunctional tumour on 68 Ga-DOTATATE finding (p=0.14),
131
I-MIBG finding (p=1.00) and 18 F-FDG finding (p=1.00).
Discussion Diagnostic Performance of Three Modalities
Similar to previous studies [14, 15] , the observed diagnostic performance of 131 I-MIBG scintigraphy in the detection of metastatic PCC/PGL on per-patient and per-lesion basis was rather disappointing.
131
I-MIBG scintigraphy remarkably underestimates the disease extent, and implies that its use as a diagnostic agent should be confined to extra-adrenal screening in patient with initial presentation of benign PCC, or assessment of patient's eligibility for 131 I-MIBG therapy [28] . Although the use of SPECT/CT in 131 I-MIBG would improve the diagnostic certainty in indeterminate lesions and contribute to better diagnostic performance than planar imaging [29, 30] , it is arguable in our study because 58.8 % (10/17) of patients showed normal scintigraphic finding where application of SPECT/CT in these patients was not required. Furthermore, the number of lesions detected by 131 I-MIBG planar images was so small that could be discretely correlated well to one of the PET/CT, CT or MRI images. However, we are aware that acquired SPECT/CT images as part of 131 I-MIBG scan would make a better fair comparison with 68 Ga-DOTATATE and 18 
F-FDG PET/CT images. Although 68
Ga-DOTATATE PET/CT demonstrates marginally better sensitivity and accuracy than 18 F-FDG PET/ CT on per-patient basis, it is significantly superior (p<0.0001) on per-lesion basis (Table 2) . Obviously, identification of metastatic disease is important in prognostication. However, accurate mapping of all metastatic lesions could have potential implication in assignment of cancer staging, and subsequent guidance in therapeutic approach. Underestimation of tumour extent could potentially lead to inappropriate management, in particular, when high risk curative metastasectomy, instead of palliative chemotherapy or targeted radiotherapy, is being carried out on a patient who is later found to have more extensive disease. Furthermore, assessment of therapeutic response requires more comprehensive evaluation of all target lesions [31, 32] . Change of any tumour volume and characteristics from the baseline may alter subsequent therapeutic approach. In sum, the significant higher diagnostic performance of 68 Ga-DOTATATE PET/ CT, on a per-lesion basis, in comparison with [14, 16, 26, 33] . Whereas, the sensitivity of 18 F-FDG is rather similar on a per-patient basis (90.9 % vs 86-88 %) but is significantly lower on per-lesion basis (51.3 % vs 74 %) [14, 16] . These discrepancies may be related to the use of different reference standards in validating the disease. In previous studies, CT or MRI, which generally have low specificity and produce inconclusive results, particularly for small lesions, were served as the reference standard. This might possibly influence the sensitivity estimates. Therefore, to overcome such imperfect standards, we adopted a composite reference standard, which derived from anatomical and functional imaging findings, along with histopathological information.
Despite comparable results of I-MIBG scintigraphy in PCC/PGL detection [34] , the lower sensitivity of 131 I-MIBG scintigraphy observed in this study could still be 18 F-FDG PET/CT was considered true positive, the specificities of all three modalities are thus, by definition, 100 % I for imaging with current gamma cameras, which contribute to poorer target-to-background ratio, and therefore possibly lower detection rate. Other factors, such as different biological properties among patients or presence of MIBGconfounding therapy, may also contribute to these discrepancies.
Studies have demonstrated that de-differentiated neuroendocrine tumours (NET) exhibit high GLUT-1 glucose transporter expression with low expression of somatostatin receptor [35, 36] . This gives the notion that somatostatin receptor expression lesions are generally associated with differentiated tumours, and as these tumours transform to more aggressive behaviour, there is shift from 68 Ga-DOTA-peptide uptake to 18 F-FDG uptake-the so called 'flip-flop' phenomenon. However, in our data, significantly more metastatic lesions with somatostatin receptor expression than glucose metabolism were detected, particularly in osseous metastases. The finding of such high detectability in metastatic lesions clearly demonstrates that somatostatin receptor expression could be link to more aggressive behaviour of tumours [23] [24] [25] . Furthermore, a recently published study also showed that a more Bcomplex relationship^exists, where matched somatostatin receptor expression and glucose metabolism lesions was seen in higher tumoural grade in NET [37] .
Interestingly, this high detectability of somatostatin receptor imaging in the detection of osseous metastases in PCC/PGL clearly contradicts a previously published study where 18 F-FDG PET was shown to be superior to 111 In-octreotide scintigraphy, a traditional somatostatin peptide imaging method [17] . It seems explicable that such a discrepancy in results is related to the use of hybrid PET/CT imaging in 68 Ga-DOTATATE, 68 Ga-DOTATATE PET/CT fusion image showed uptake in the aortocaval soft tissue mass (SUVmax 6.7) but 18 F-FDG PET/ CT fusion image showed no FDG avidity (arrow). The lesion was later confirmed to be metastasis on resection which provides better spatial resolution and image quality, leading to higher lesional detectability compared to conventional gamma imaging with 111 In-octreotide [38, 39] Ga-DOTATA TE expectably contributes the most (Fig. 3) . All of these findings illustrate the important point that there is considerable inter-/intra-tumoural heterogeneity in malignant PCC/PGL, and the relationship among 68 Ga-DOTATATE, 131 I-MIBG and 18 F-FDG is not as straightforward as previously thought. The findings of somatostatin receptor expression in a large number of metastatic lesions, including mixed (differentiated and de-differentiated) lesions, suggest that somatostatin receptors may be an independent receptor expression in PCC/PGL cellular differentiation process, which is not solely confined to well-differentiated phenotype.
The limitation of this study is a relatively small sample size that hinders further analysis. However, it was justified by the rarity of the disease. Apart from that, the high number of lesions in a small number of patients could also introduce sampling bias and might subsequently influence the determination of sensitivity and accuracy estimate.
Another limitation was a considerably long study interval among the examinations in some patients. This was unavoidable considering the different locations of the individual examinations, the high workload and waiting time in public hospitals and the patients' places of origin from different states.
Although every effort was made to recruit all eligible patients, the possibility of selection and ascertainment bias (such as known prior disease status or previous imaging results used as a basis for recruitment) cannot be excluded.
The verification of the diagnostic performance of an index test could be a strenuous undertaking when the gold standard is not available or imperfect. An attempt has been made to produce more meaningful results in clinical practice by adopting a composite reference standard. However, the possibility of reference-standard-related bias (such as misclassification of lesions, or error and variation in image interpretation) cannot be totally excluded.
Conclusions
Although a multimodality approach using different radiotracers could provide imaging of real disease extension in malignant PCC/PGL, it is time-consuming, impractical and not cost-effective. The high sensitivity and accuracy in 68 Ga-DOTATATE PET/CT implies that somatostatin receptor PET/ CT imaging may offer a better overview on tumour spread and extension than 131 I-MIBG and 18 F-FDG. 68 Ga-DOTATATE PET/CT should be recommended into the standard algorithm of evaluation such tumours.
In addition,
68
Ga-DOTATATE PET/CT provides valuable information on somatostatin receptor status in this group of patients when peptide receptor radionuclide therapy (PRRT) is being considered as part of the multimodal management in metastatic PCC/PGL [40, 41] . High detectability of somatostatin receptor expression lesions in metastatic PCC/ PGL provides the basis for consideration of PRRT as initial therapeutic strategy.
Lastly, a prospective controlled multicentre study with a larger patient group would be beneficial in future. With the advent of genetic testing in PCC/PGL, potential relationship between 68 Ga-DOTATATE PET/CT results and genetic abnormalities would provide a more comprehensive understanding of the correlation between germline mutation and tumour characteristics.
